Adc Therapeutics Sa Adc Therapeutics Doses First Patient In Pivotal Clinical | Latest News RSS feed

Adc Therapeutics Sa Adc Therapeutics Doses First Patient In Pivotal Clinical - Latest News


ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas

The first stage is a dose escalation phase which will recruit up to 30 patients ... clinical trials, with a deep pipeline of other ADCs in preclinical development. More information regarding these tri... read more

ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-402 for Patients with B-cell lineage Acute Lymphoblastic Leukemia

The first stage (Phase Ia) is a dose escalation ... Ia/Ib clinical trials in patients with relapsed or refractory B-cell lineage non-Hodgkin lymphoma and relapsed or refractory B-cell lineage acute ly... read more

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

The overall response rate with doses ... clinical trials in patients with relapsed or refractory B-cell lineage non-Hodgkin lymphoma and relapsed or refractory B-cell lineage acute lymphoblastic leuke... read more

Looking for another news?


ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been ... read more


Why Celldex Therapeutics Is A Buy (Part 2)

Shares of Celldex Therapeutics ... to the first patient in Phase 1 clinical trial focused on patients with gastrointestinal stromal tumors (or GIST) and other tumors expressing KIT. The trial is desig... read more

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for Its Second Novel Antibody Drug Conjugate ADCT-402 against Lymphomas and Leukemia

LAUSANNE, Switzerland & LONDON & MURRAY HILL, N.J.--(BUSINESS WIRE)--ADC Therapeutics SA (ADCT ... single doses, and it outperformed other CD19 targeted ADCs currently in clinical development. The fir... read more

ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML

"Patients with multiply relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma have limited treatment options. These early findings are very encouraging as they demonstrate a clear clinical benefi... read more

An Ear To The Pharma: 12 Stocks To Watch (AIMT, TXMD, MDGL…)

Watch out for… The first ... clinical stage biopharmaceutical company developing novel oncology therapeutics that target difficult to treat cancers. The Company's pipeline includes SL-401, which has s... read more

Sorrento Therapeutics: Has The Potential To Become Next Abraxis

The first cycle of the trial will involve 50 patients ... therapeutics market. The strategy to pursue both internal development and partnership at the same time will mitigate the development risks for ... read more

Immunomedics Reports Updated Results of Labetuzumab-SN-38 in Metastatic Colorectal Cancer

Only 5 patients to-date have been evaluated after completing therapy with 4 or more doses of the ADC ... pivotal trial for clivatuzumab labeled with a radioisotope in advanced pancreatic cancer patien... read more

Sorrento: Multiple Progresses Have Been Made

On March 31, 2014, Sorrento Therapeutics (SRNE) announced that the first patient has been dosed in the pivotal clinical trial of Cynviloq for the ... Sorrento’s G-MAB ® and ADC platforms have great po... read more

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

First Clinical Data of ADCT-402 Demonstrate Encouraging Antitumor Activity in Relapsed or Refractory Non-Hodgkin's Lymphoma LAUSANNE, SWITZERLAND / ACCESSWIRE / June 16, 2017 / ADC Therapeutics ... wi... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us